Spots Global Cancer Trial Database for A Study of Darbepoetin Alfa in Patients With Myelodysplastic Syndrome (MDS)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of Darbepoetin Alfa in Patients With Myelodysplastic Syndrome (MDS)
Official Title: A Study of Darbepoetin Alfa in Patients With Myelodysplastic Syndrome (MDS)
Study ID: NCT00230321
Interventions
Study Description
Brief Summary: The primary objectives of the trial are to assess erythroid response to darbepoetin alfa, as determined by changes in hemoglobin and/or red blood cell (RBC) transfusion-dependence and to describe the safety profile of darbepoetin alfa in patients with MDS. The secondary objective is to assess bone marrow progenitor BFU-E growth before and after treatment with darbepoetin alfa.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Stanford University School of Medicine, Stanford, California, United States
Contact Details
Name: Peter L Greenberg
Affiliation: Stanford University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
